CEL-SCI Co. (CVM) Short Interest Down 7.0% in March

CEL-SCI Co. (NYSEAMERICAN:CVM) was the recipient of a large decline in short interest in March. As of March 15th, there was short interest totalling 897,860 shares, a decline of 7.0% from the February 28th total of 965,285 shares. Approximately 5.7% of the company’s stock are sold short. Based on an average daily trading volume, of 72,978 shares, the short-interest ratio is currently 12.3 days.

A hedge fund recently bought a new stake in CEL-SCI stock. Anson Funds Management LP purchased a new position in CEL-SCI Co. (NYSEAMERICAN:CVM) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 263,158 shares of the company’s stock, valued at approximately $423,000. CEL-SCI makes up 0.3% of Anson Funds Management LP’s investment portfolio, making the stock its 27th largest holding. Anson Funds Management LP owned approximately 1.88% of CEL-SCI at the end of the most recent reporting period.

How to Become a New Pot Stock Millionaire

Shares of CVM stock opened at $1.50 on Tuesday. CEL-SCI has a fifty-two week low of $1.46 and a fifty-two week high of $4.00. The company has a market cap of $25.49, a price-to-earnings ratio of -0.55 and a beta of -1.29.

CEL-SCI (NYSEAMERICAN:CVM) last announced its earnings results on Monday, February 12th. The company reported ($0.53) EPS for the quarter. The firm had revenue of $0.11 million for the quarter.

WARNING: “CEL-SCI Co. (CVM) Short Interest Down 7.0% in March” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3303399/cel-sci-co-cvm-short-interest-down-7-0-in-march.html.

CEL-SCI Company Profile

CEL-SCI Corporation is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company is focused on activating the immune system to fight cancer and infectious diseases. It operates through the segment of research and development of certain drugs and vaccines.

Receive News & Ratings for CEL-SCI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Fonziecoin  Price Hits $0.0011 on Major Exchanges
Fonziecoin Price Hits $0.0011 on Major Exchanges
RioCan Real Estate Investment Trust  Raises Dividend to $0.12 Per Share
RioCan Real Estate Investment Trust Raises Dividend to $0.12 Per Share
Exchange Income Co.  Increases Dividend to $0.18 Per Share
Exchange Income Co. Increases Dividend to $0.18 Per Share
Energy Leaders Plus Income Fund to Issue Monthly Dividend of $0.03
Energy Leaders Plus Income Fund to Issue Monthly Dividend of $0.03
Stifel Nicolaus Boosts Align Technology  Price Target to $320.00
Stifel Nicolaus Boosts Align Technology Price Target to $320.00
Integra lifesciences  Stock Rating Reaffirmed by Citigroup
Integra lifesciences Stock Rating Reaffirmed by Citigroup


© 2006-2018 Ticker Report. Google+.